In short
Clinical trials investigating Linagliptin are studying its use in several patient groups, including people with type 2 diabetes, heart failure, and metastatic non-small cell lung cancer. These studies look at safety, treatment effects, and specific outcomes such as blood sugar control, heart-related measures, and response to treatment.
Key points
- Clinical trials investigating Linagliptin are shown in different disease areas, not only diabetes. The studies include people with type 2 diabetes, heart failure with reduced ejection fraction, and metastatic non-small cell lung cancer. Trial phases range from low-intervention and Phase 1 to Phase 3, so the research includes both early and later-stage studies. The main outcomes include blood sugar control, cancer response, heart-related safety and effectiveness measures, and kidney-related safety events. Some trials study Linagliptin as part of treatment combinations, while others include it among several treatment options in comparison groups.
Clinical trial overview
The trial data show that Linagliptin is being studied in different research settings, mostly in people with type 2 diabetes, but also in studies involving heart failure and metastatic non-small cell lung cancer.
These studies are not all the same. Some compare treatment strategies, some test whether a treatment plan works better than another, and some look at safety and response outcomes in specific patient groups.
Conditions studied in the trials
One completed study looked at people with heart failure with reduced ejection fraction, a condition where the heart pumps less strongly than normal. That trial studied treatment initiation strategies and included Linagliptin in one of the listed drug combinations.
Another completed study focused on metastatic non-small cell lung cancer, which means lung cancer that has spread to other parts of the body. In that study, Linagliptin appeared as Trajenta in a treatment combination used in a Phase 1 cancer trial.
Several authorised studies focused on type 2 diabetes or type 2 diabetes mellitus. These studies examined blood sugar control and other diabetes-related outcomes, and Linagliptin was one of the listed treatment options in some of them.
Trial phases and study designs
The trial set includes a low-intervention study, a Phase 1 study, and several Phase 3 studies. Low-intervention means the study adds little beyond regular care, while Phase 1 and Phase 3 describe early and later stages of clinical research.
The heart failure study was a randomized open-label trial, which means participants were assigned to treatment strategies by chance and both the researchers and participants knew which treatment was given. The cancer study was interventional and focused on objective response rate in Stage 1.
The diabetes studies were also interventional and aimed to compare treatment approaches or to test whether a personalized strategy improves control in people with not well controlled diabetes.
What the trials measure
The main outcome in the heart failure study was a composite outcome, which means several important events were grouped together into one result. These events included low blood pressure, changes in potassium, kidney function decline, need for more diuretics, hospital stay for worsening heart failure, and death from cardiovascular causes.
The cancer study measured objective response rate (ORR), which shows how many patients had their tumors shrink or disappear after treatment. This is a common way to check whether a cancer treatment is having an effect.
In the diabetes studies, one trial measured the proportion of patients who reached HbA1c of 7% or less at Week 24. Another trial measured change in HbA1c from baseline, which means the study compared blood sugar control before and after treatment.
One Phase 3 diabetes study also measured heart-related and nerve-related outcomes, including the LF:HF ratio and CART parameters, which are tests used to assess cardiovascular autonomic neuropathy and heart rate control. It also looked at glucose variability, meaning how much blood sugar levels rise and fall over time.
Who the trials include
The trials focus on adult patients or disease-specific groups, depending on the study. For example, the heart failure study included patients with HFrEF or HFmrEF, while the diabetes studies focused on people with type 2 diabetes and insufficiently controlled blood sugar.
The cancer study enrolled patients with metastatic non-small cell lung cancer. The trial data do not give full eligibility rules here, so the exact inclusion and exclusion criteria would need the full study record for each trial.
Linagliptin in combination studies
In the available trial data, Linagliptin is often listed as one treatment option among several drugs being studied. This means the research is not always testing Linagliptin alone; sometimes it is part of a broader treatment strategy or comparison arm.
For example, the heart failure trial compared different initiation strategies that included drug combinations, and the diabetes studies listed Linagliptin alongside other diabetes treatments such as sitagliptin, semaglutide, pioglitazone, and insulin products.
Because the source data only provide trial summaries, the exact role of Linagliptin in each study arm is not fully described here.
Patient-focused summary of the research
Overall, the trial data show that Linagliptin is being studied across different diseases and research questions, from blood sugar control to cancer response and heart failure safety.
The most important patient-level outcomes in these studies are whether treatment helps, whether it is safe, and whether it improves measurable health markers such as HbA1c, kidney function, heart rhythm balance, or tumor response.